More than six months after the World Health Organization (WHO) declared a Public Health Emergency of International Concern (PHEIC) in response to the emergence of SARS-CoV-2, also known as COVID-19. Has passed. PHEIC is the most serious indicator of the health risks of the international community.
Comprehensive data were difficult to compile due to lack of standardized testing and reporting, but WHO said there were more than 24.3 million confirmed cases worldwide and more than 800,000 deaths. I’m estimating. SARS-CoV-2 virus..
SARS-CoV-2: Struggle for Rapid Diagnosis
So far, regional and international efforts have focused on containing the virus to limit its spread. However, this is basically a retention method.
Researchers are working on the development of appropriate prophylactic interventions using structural proteins, and this approach is at the forefront of the ongoing battle against SARS-CoV-2. This tactic was also adopted with the aim of developing strategies to address other respiratory illnesses such as SARS-CoV and MERS.
Through hard-working research and development (R & D), the ACRO Biosystems team has a series of SARS-CoV-2 antigen protein For COVID-19 diagnosis. Many recognized test methods (eg, reverse transcription-polymerase chain reaction (RT-PCR)) use RNA templates to detect the SARS-CoV-2 gene, which results in relatively inconvenient and time-consuming. Will be charged.
In contrast, however, detection of antibodies and antigens of COVID-19 infection is much faster, facilitating faster diagnosis. Some kits are even approaching immediate detection.
SARS-CoV-2 antigen protein
Team The ACRO Biosystems team has been working hard since the SARS-CoV-2 genomic sequence was first published, creating a suite of high-quality recombinant proteins, nucleocapsid protein antigens, and spike glycoproteins.
these SARS-CoV-2 antigen protein They are derived from E. coli or HEK293 cell lines, respectively. These are recommended for a wide range of antibody detection methods, including enzyme-linked immunosorbent assay (ELISA), chemiluminescent immunoassay, and gold immunochromatography.
Serological systems such as these are designed to improve the speed of SARS-CoV-2 screening techniques and provide fully validated bioactivity with excellent consistency between batches. ..
Thanks to the ongoing work, ACRO Biosystems is now able to provide free samples to researchers working on the development of advanced diagnostic kits for COVID-19.
ACRO Biosystems Is a leading manufacturer of recombinant proteins and other important reagents that support the development of targeted therapeutics. The company employs an application-oriented development strategy with a particular focus on product design, quality control, and solution-based support. Our products and services allow anyone in the field of drug development to have a more intuitive and streamlined process.
To address the coronavirus pandemic, ACRO Biosystems has developed SARS-CoV-2 antigens specifically designed and optimized for serological test kits such as spike-derived antigens S1, RBD, and nucleocapsid proteins. .. Protein has been supplied in large quantities to diagnostic companies.
Sponsored Content Policy: News-Medical.net publishes articles and related content derived from existing sources of business relationships. However, only if such content adds value to News-Medical.Net’s core editorial ethics of educating and notifying site visitors with medical interests. Research, science, medical devices and treatment.